Akeso starts dosing AK146D1-AK112 combination in advanced NSCLC
The Phase 2 trial pairs Akeso's ADC with its approved bispecific ivonescimab, testing a combination in a lung cancer field already dense with PD-1-directed programs.
Executive Summary
- Akeso began dosing patients in a Phase 2 trial combining a new antibody-drug conjugate with its already-advanced PD-1/VEGF-A bispecific in advanced lung cancer, moving the study from not-yet-recruiting to actively enrolling.
- The combination tests whether pairing an ADC with a clinically established bispecific can extend that bispecific's activity, a readthrough that matters more for the partner drug's broader positioning than for this trial alone.
- The trial enters a PD-1-targeted lung cancer field with dozens of industry peers already in Phase 2 or later, meaning the combination will need a differentiated response signal to stand out rather than novelty of mechanism.
- The trial's start date and completion timeline tracked the sponsor's own registry guidance without slippage, a normal operational signal rather than a red flag.
The trial
The study, registered as NCT07669779, moved from Not yet recruiting to Recruiting status on July 14, 2026, with the first patient dosed on July 10, 2026. The trial targets 348 patients with locally advanced or metastatic non-small cell lung cancer who are not candidates for curative surgery or definitive chemoradiotherapy. It runs in China, with a primary completion date of August 30, 2027. NCT07669779A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerNCT07669779
The design
The trial's primary endpoints are safety-focused: the incidence of adverse events, and dose-limiting toxicities assessed during the first three weeks of a safety run-in phase. Objective response rate assessed by RECIST v1.1 is also listed as primary, alongside secondary measures including disease control rate, duration of response, overall survival, and progression-free survival, each followed for up to approximately two years. That combination of a dose-finding safety bar with an early efficacy readout is typical for a Phase 2 study introducing a new combination partner. NCT07669779A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerNCT07669779
What it tests
AK146D1 is an antibody-drug conjugate; AK112 (ivonescimab) is a PD-1/VEGF-A bispecific antibody already advanced in lung cancer development, including in a Phase 3 trial sponsored by Summit Therapeutics that reaches primary completion in April 2025. The trial tests whether adding an ADC's cytotoxic payload to a bispecific checkpoint-and-angiogenesis blocker compounds toxicity or extends the combination's activity beyond what ivonescimab alone has shown, a tolerability and activity question the safety run-in phase and its adverse-event and dose-limiting-toxicity endpoints are designed to answer. NCT07669779A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerNCT07669779
The competitive field
PD-1-directed programs in non-small cell lung cancer are extensive: 64 industry trials share the PD-1 target and NSCLC indication, with 42 already at Phase 2 or beyond. Direct comparators include pembrolizumab, nivolumab, and Merck's sacituzumab tirumotecan, all in Phase 3 testing in the same indication. Against that field, a status change alone carries limited differentiation; the trial's value will depend on the response and safety data it produces relative to that established competitive set.
Operational context
The trial's timeline held steady through the status change: its primary completion date remained August 30, 2027 both before and after the transition to Recruiting, and the registry shows no protocol amendments beyond the status update itself. Akeso has completed 65 of 73 trials globally, with 8 terminated, a track record that provides context for the sponsor's broader execution but does not by itself say anything about this specific combination's prospects. NCT07669779A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerNCT07669779
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.